Efficacy and safety of botulinum toxin injection in reducing deltoid muscle hypertrophy

Dermatol Ther. 2021 Nov;34(6):e15168. doi: 10.1111/dth.15168. Epub 2021 Oct 26.

Abstract

With the increasing demand for body contouring, botulinum toxin (BTX) injection is being widely used off-label for muscular hypertrophy. However, to the best of our knowledge, no study has investigated the clinical efficacy of BTX type A (BTX-A) in deltoid muscle hypertrophy. This study was conducted to evaluate the efficacy and safety of intramuscular injection of BTX in reducing deltoid muscle hypertrophy. Overall, 10 patients with bilateral deltoid muscle hypertrophy were treated with an intramuscular injection of prabotulinum toxin A, with a total of 50 units [U] administered per patient. As measured by ultrasonography, the thickness of the deltoid muscles was significantly decreased at weeks 2 and 12. In addition, the clinical assessment score by blinded investigators was improved after the treatment; however, patients' satisfaction scores were relatively low. No major complications were reported. Therefore, intramuscular injection of BTX-A seems to be a candidate for novel treatment option for deltoid muscle hypertrophy. Further larger clinical studies are warranted to confirm the efficacy of BTX-A.

Keywords: aesthetic medicine; body contouring; botulinum toxin; deltoid muscle; muscle hypertrophy.

MeSH terms

  • Botulinum Toxins, Type A*
  • Deltoid Muscle* / drug effects
  • Humans
  • Hypertrophy* / drug therapy
  • Injections, Intramuscular
  • Treatment Outcome

Substances

  • Botulinum Toxins, Type A